List of works by Ian E Krop

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer

scientific article published on 30 January 2020

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.

scientific article published on 27 January 2014

A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases

scientific article published on 22 June 2011

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

scientific article

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer ⬇️

scientific article

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

scientific article published on 3 January 2018

Author's reply: Use of discard pleural fluid in molecular research

scientific article published on January 2012

CDK4/6 inhibition triggers anti-tumour immunity.

scientific article published on 16 August 2017

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

scientific article published on 16 May 2015

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study

scientific article

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

scientific article published on 06 June 2016

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?

scientific article published on November 2007

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

scientific article published on 03 September 2020

Genomic characterization of de novo metastatic breast cancer

scientific article published on 08 December 2020

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

scientific article published on 15 November 2019

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

scientific article

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

scientific article published on 23 July 2018

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

scientific article

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction

scientific article published on 13 September 2013

Ovarian suppression for breast cancer: an effective treatment in search of a home

scientific article published on 8 August 2005

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

scientific article published on March 2016

Personalization of loco-regional care for primary breast cancer patients (part 1).

scientific article published in January 2015

Personalization of loco-regional care for primary breast cancer patients (part 2).

scientific article published on January 2015

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

scientific article published on 02 November 2020

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

scientific article

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr

scientific article

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

scientific article

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

scientific article published on 30 November 2020

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

scientific article

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022

scientific article published on 22 August 2019

Prospective clinical experience with research biopsies in breast cancer patients

scientific article published on 11 October 2013

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

scientific article published on 18 June 2020

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update

scientific article published on 25 June 2018

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

scientific article published on 6 January 2016

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

scientific article

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

scientific article published on 02 April 2019

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

scientific article published on 01 June 2020

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

scientific article published on 23 October 2020

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update

scientific article published on 25 June 2018

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

scientific article published on 12 March 2019

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

scientific article published on 25 February 2020

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

scientific article published on 29 October 2020

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

scientific article published 2019

Ten years of HER2-directed therapy: still questions after all these years

scientific article published on 8 May 2008

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy

scientific article published on 06 May 2019

The ethical use of mandatory research biopsies

scientific article published on 2 August 2011

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

scientific article published on February 2016

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study

scientific article

Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer

Paulina is supported by:

About Paulina

Help